Kyntra Bio, Inc. KYNB
3.78 USD +0.09 (+2.58%)
Nov 12, 2026, 12:05 PM EST
3.67 Day range 3.78
3.50 52-week range 10.47
- YTD
- -57.00%
- 1 year
- -58.65%
News
defenseworld.net Kyntra Bio Inc (NASDAQ:KYNB) Stock Has Average Price Target of $36.80 According to Analysts Kyntra Bio Inc (NASDAQ: KYNB - Get Free Report) has earned an average rating of "Hold" from the seven analysts that are currently covering the stock, Marketbeat Ratings reports. Two analysts have…- benzinga.com Maxim Group Initiates Coverage On Kyntra Bio with Buy Rating, Announces Price Target of $35 Maxim Group analyst Michael Okunewitch initiates coverage on Kyntra Bio (NASDAQ:KYNB) with a Buy rating and announces Price Target of $35.
benzinga.com Lake Street Initiates Coverage On Kyntra Bio with Buy Rating, Announces Price Target of $41 Lake Street analyst Daniel Brims initiates coverage on Kyntra Bio (NASDAQ:KYNB) with a Buy rating and announces Price Target of $41.
benzinga.com HC Wainwright & Co. Reiterates Buy on Kyntra Bio, Maintains $43 Price Target HC Wainwright & Co. analyst Matthew Keller reiterates Kyntra Bio (NASDAQ:KYNB) with a Buy and maintains $43 price target.- benzinga.com Kyntra Bio To Reduce The Maximum Aggregate Payments Under Its Royalty Financing Agreement From $125M To $65M; Co. Accelerated Payment Of $42.6M Upfront, Bringing Total Payments Made To Date To $50M; Remaining Payments, Capped At $15M, To Be Paid From 50% Of The Revenue Received From Astellas In The Astellas Territories Excluding Japan Company reduces the maximum aggregate payments under its royalty financing agreement from $125 million to $65 million Company accelerated payment of $42.6 million upfront, bringing total payments…
benzinga.com UPDATE: Kyntra Bio Q2 Adj. EPS $(4.68) Misses $(3.18) Estimate, Sales $(1.474M) Miss $2.007M Estimate Kyntra Bio (NASDAQ:KYNB) reported quarterly losses of $(4.68) per share which missed the analyst consensus estimate of $(3.18) by 47.17 percent. This is a 148.94 percent decrease over losses of…
benzinga.com Kyntra Bio Q2 2026 Earnings Call: Complete Transcript On Thursday, Kyntra Bio (NASDAQ:KYNB) discussed second-quarter financial results during its earnings call. The full transcript is provided below. Benzinga APIs provide real-time access to earnings…
benzinga.com This Performance Food Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday Wall Street analysts changed outlook on top names. See analyst rating changes on top stocks. PFGC, SPCX, KC, WELL, KYNB have coverage initiated.- benzinga.com Oppenheimer Initiates Coverage On Kyntra Bio with Outperform Rating, Announces Price Target of $35 Oppenheimer analyst Jay Olson initiates coverage on Kyntra Bio (NASDAQ:KYNB) with a Outperform rating and announces Price Target of $35.
benzinga.com Kyntra Bio Presents New Data For Roxadustat Showing Improvements In Transfusion Independence Regardless Of Ring Sideroblast Status In Anemia Patients The presentation at EHA also provides additional details on the subgroup of patients (n=37) who met the criteria of HTB (≥ 4 units pRBCs per 8-week period for 2 consecutive 8-week periods) per…- benzinga.com Rodman & Renshaw Initiates Coverage On Kyntra Bio with Buy Rating, Announces Price Target of $30 Rodman & Renshaw analyst Michael G. King Jr. initiates coverage on Kyntra Bio (NASDAQ:KYNB) with a Buy rating and announces Price Target of $30.
- benzinga.com Kyntra Bio Q1 EPS $(3.76) Down From $1.15 YoY, Sales $3.738M Up From $2.739M YoY Kyntra Bio (NASDAQ:KYNB) reported quarterly losses of $(3.76) per share. This is a 426.96 percent decrease over earnings of $1.15 per share from the same period last year. The company reported $3.738…
benzinga.com Earnings Scheduled For May 11, 2026 
benzinga.com Kyntra Bio Q4 EPS $(3.61) Beats $(3.71) Estimate, Sales $1.300M Miss $1.425M Estimate Kyntra Bio (NASDAQ:KYNB) reported quarterly losses of $(3.61) per share which beat the analyst consensus estimate of $(3.71) by 2.56 percent. This is a 80.5 percent decrease over losses of $(2.00)…- benzinga.com Earnings Scheduled For March 16, 2026
benzinga.com What's Going On With Kyntra Bio Stock Tuesday? Kyntra Bio announces positive data for FG-3246 plus enzalutamide in metastatic castration-resistant prostate cancer.